Tegio is a common dosage form with tablets and capsules. It is an antitumor drug, mainly used for the treatment of advanced or metastatic cancer, and has a good effect on the treatment of nasopharyngeal carcinoma. The main ingredients of Tegio are Tegafur, Gimepiridine and Potassium Otelacil. Tegio has anti-tumor effects, and has the effect of inhibiting tumor proliferation for gastric cancer, colorectal cancer, breast cancer, lung cancer, pancreatic cancer, kidney cancer subcutaneous transplantation tumor (nude mice). Its mechanism of action is a compound preparation composed of Tegafur, Gimepyrimidine and Potassium Otilacil, after oral administration Tegafur is slowly converted to 5-FU in the body and exerts anti-tumor effects. When using Tegafur in the treatment of cancer, it has relatively low side effects on the human body, has the ability to maintain high blood concentration for a longer period of time, and usually has a good effect of clinical chemotherapy on nasopharyngeal carcinoma. Patients with severe bone marrow suppression, patients with severe renal function abnormalities, patients with severe hepatic function abnormalities, patients undergoing treatment with other fluorouracil antineoplastic drugs, patients undergoing treatment with flucytosine, patients undergoing treatment with sorivudine and its structural analogs (bromovudine), the drug is prohibited for all of the above patients and pregnant women during pregnancy. Tegeo is a prescription drug and should be used under the supervision of a doctor if needed to minimize the risks of using the drug.